




Synthesis, antimicrobial, anticancer evaluation and molecular docking with Bax and MDM2 of dibromosterculic acid

Rahul Bose^a, Ayan Paul^a, Rajashree Dutta^a, Anjan Hazra^a, Arindam Pramanik^{b,c} and Suparna Mandal Biswas^a 

^aAgricultural and Ecological Research Unit, Indian Statistical Institute, Kolkata, India; ^bSchool of Medicine, University of Leeds, United Kingdom; ^cAmity Institute of Biotechnology, Amity University, Uttar Pradesh, India

ABSTRACT


Dibromosterculic acid [8-(1,2-dibromo-2-octylcyclopropyl)-octanoic acid], a new synthetic derivative was prepared by bromination of sterculic acid. This synthetic derivative showed strong fungicidal activity against two pathogenic fungal species namely *Penicillium chrysogenum* and *Aspergillus niger* with minimum inhibitory concentration (MIC) value of 0.007 mg/ml and good bactericidal activity against *Bacillus subtilis* and *Xanthomonas sp.* with MIC value of 0.015 mg/ml. Cytotoxic activity on both normal (MCF-10A) and cancerous (MDA-MB-468) cell lines revealed that the survivability percentage of normal cells was unaffected, whereas cancerous cells were decreased greatly by dibromosterculic acid with 50% survivability at 9 µg/ml concentration. Molecular-docking using AutoDock 4.2 with Bax exhibited strong pi-sigma interaction with PHE-93, pi-alkyl and alkyl interaction with TRP-139, ARG-89 and PHE-92 whereas MDM2 revealed strong hydrogen bond interaction with GLN-59 and pi-alkyl interaction with PHE-55. All experimental parameters suggested that this synthetic derivative would be valuable for target-specific drug development with nominal side effects.

ARTICLE HISTORY


Received 26 December 2022
Accepted 4 December 2023

KEYWORDS

Sterculia foetida; L.; dibromosterculic acid; cytotoxicity; molecular-docking; Bax; MDM2 (p53 inhibitor)



CONTACT Rahul Bose  rahulbosebiotech@gmail.com; Suparna Mandal Biswas  mondalsupa@gmail.com

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/14786419.2023.2294107>.

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

© 2023 Informa UK Limited, trading as Taylor & Francis Group